Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jun 26, 2026, 7:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: ET-MF Clear all

Conditions: Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
Interventions: TL-895, Ruxolitinib; Drug
Lead sponsor: Telios Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Birmingham, Alabama • Canton, Ohio • Cincinnati, Ohio + 1 more

Conditions: Leukemia, Myelofibrosis, Anemia, Splenomegaly
Interventions: Rigosertib, Questionnaire; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions: NS-018; Drug
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Diego, California • Jacksonville, Florida + 5 more

Conditions: Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis
Interventions: MMB; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 14
States / cities: Scottsdale, Arizona • Orange, California • Stanford, California + 11 more

Conditions: Myelofibrosis, Polycythemia Vera, Thrombocythemia
Interventions: itacitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: New Orleans, Louisiana • Bethesda, Maryland • Kansas City, Missouri + 5 more

Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions: PU-H71; Drug
Lead sponsor: Samus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Larkspur, California • Los Angeles, California • Houston, Texas

Conditions: Polycythemia Vera, Thrombocythemia
Interventions: CC-4047, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: FEDRATINIB; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Aurora, Colorado • Miami, Florida • Augusta, Georgia + 23 more

Conditions: Myelofibrosis, Essential Thrombocythemia, MPN
Interventions: Peptide-based vaccine, Poly ICLC; Drug
Lead sponsor: Marina Kremyanskaya; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Interventions: KRT-232, Best Available Therapy (BAT); Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 14 more

Conditions: Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Post-Essential Thrombocythemia Related Myelofibrosis
Interventions: LBH589; Drug
Lead sponsor: Ronald Hoffman; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
Interventions: LOXL2 Inhibitor PAT-1251, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
Interventions: KRT-232, TL-895; Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 6
States / cities: Birmingham, Alabama • Whittier, California • Lake City, Florida + 3 more

Conditions: Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Interventions: reparixin; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Tampa, Florida • Atlanta, Georgia • Buffalo, New York + 4 more

Search by objective public record fields.

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Extended Access of Momelotinib in Adults With Myelofibrosis

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Pomalidomide for Myelofibrosis Patients

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)